Editas Q3 2023 Earnings Report
Key Takeaways
Editas Medicine reported a net loss of $45.0 million, or $0.55 per share, for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $446.4 million as of September 30, 2023, which is expected to fund operations into the third quarter of 2025. Collaboration and other research and development revenues increased to $5.3 million due to an upfront payment from Vor Bio.
Advanced EDIT-301 clinical program, continuing patient enrollment and dosing.
Expects EDIT-301 to be a clinically differentiated, one-time, durable medicine.
Plans to share clinical data from RUBY and EdiTHAL trials at ASH and in a Company-sponsored webinar in December.
Appointed Caren Deardorf as Chief Commercial and Strategy Officer.
Editas
Editas
Editas Revenue by Segment
Forward Guidance
Editas Medicine expects its cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into the third quarter of 2025.